Javier Zulueta, MD, right, is joined by, from left, Rahul Agarwal, MD, and Fernando Carnavali, MD.
Lung cancer is by far the leading cause of cancer deaths in the United States accounting for about one in five cancer deaths. It is difficult to detect because there are often no symptoms in its earliest stages—only 16 percent of lung cancers in the United States are detected at a localized stage.
Lung cancer screening for smokers and former smokers, like the Early Action Lung Cancer Action Program (I-ELCAP), has been found effective in detecting lung cancer at earlier stages. However, as more lung cancers are being detected in non-smokers and many are ineligible for screening under the I-ELCAP guidelines, additional tools are needed to detect lung cancers early and save lives.
The newly launched Incidental Lung Nodule Program (ILNP) at Mount Sinai Morningside opens a new path for early detection guided by methodically identifying the patients with lung nodules at most risk for lung cancer and ensuring they receive timely interventions.
How the Incidental Lung Nodule Program Works
CT scans ordered for other illnesses and injuries are methodically scanned by computerized search—a more equitable and inclusive tool for detecting lung cancer early. All of those scans with a reported and documented incidental lung nodule are reviewed by a team led by a pulmonologist with special expertise in lung nodules.
Research has shown that about 25 percent of individuals who have a CT scan of the chest will have an incidental lung nodule detected, most of which need follow-up. Approximately five percent of the individuals with lung nodules may have lung cancer. With an early diagnosis, lung cancer can be successfully treated in the majority of patients.
All scans with findings are entered into a database for tracking and follow-up. The ILNP team notifies the ordering physician and the patient’s primary care provider, if available, via Epic, phone call, or letter, with a specific follow-up recommendation. If the ordering physician was in the Emergency Department and there is no primary care provider available, the ILNP team will reach out to the patient directly.
Click here to see a flowchart showing the communication pathway.
How Do Patients Seek Evaluation and Treatment
Javier Zulueta, MD, a lung nodule expert and pulmonologist at Mount Sinai Morningside, leads a multidisciplinary clinic that accepts referrals from physicians and is available directly to patients. Patients who need evaluation by the nodule clinic will be offered an appointment within one week of notification. They will be evaluated by a pulmonary specialist, and a plan will be established according to guidelines, including a wide variety of diagnostic and treatment options depending on the characteristics of the nodule:
Blood test for cancer biomarkers
PET scan
Pulmonary function tests
Biopsy by robotic bronchoscopy or CT guidance
Evaluation by Thoracic Surgery
Smoking cessation will be offered to anyone who is a current smoker. All patients will be given a plan for CT scan follow-up within a predetermined period of time—anywhere between three and 12 months.
Patients may require exam and follow-up or diagnostic interventions like image-guided bronchoscopy or percutaneous biopsy. If cancer is diagnosed, the patient will be presented at Mount Sinai Morningside’s weekly multidisciplinary lung cancer and nodule conference. After review of all diagnostic and staging tests, a decision regarding treatment will be made. This can vary depending on the stage but includes thoracic surgery for early stages and oncologic assessment for all.
Patient Follow-Up
Patient not requiring immediate care will be prompted to repeat their CT scan on a recommended schedule and will continue to receive evaluation through the ILNP. The ILNP program navigators will contact the primary care physician, other provider, or the patient directly if patient is not getting the recommended diagnostics.
For more information or to refer a patient to the Lung Nodule Clinic, please call 212-523-3589.
The maternal and fetal wireless technology is a single patch system placed on the birth parent’s abdomen.
Wireless technology has transformed virtually all aspects of our life, and now it is ready to transform the birthing and labor experience.
Mount Sinai West recently launched advanced wireless monitoring technology that allows patients the freedom to safely move around during the labor process.
The maternal and fetal wireless technology is a single patch system placed on the birth parent’s abdomen, allowing providers and nurses to monitor fetal heart rate, contractions, and uterine activity while offering patients more freedom of movement during the birth experience.
This technology is a cord-free, belt-free solution that increases the comfort of laboring patients. Without cords connecting the patient to a fetal monitor, laboring patients are free to get up, move around their room or the hospital, and change positions as needed. It can even be worn in the shower or tub. The Mount Sinai Hospital will soon offer this service to patients.
“Wireless technology has become a standard for all things modern. By utilizing wireless monitoring, we can significantly increase our patients’ comfort and mobility,” says Desmond Sutton, MD, Medical Director, Labor and Delivery in the Department of Obstetrics and Gynecology at Mount Sinai West and Assistant Professor of Obstetrics and Gynecology at the Icahn School of Medicine at Mount Sinai. “This really transforms the birth and labor experience, and we are pleased to have it available to all patients.”
The small device, about the size of computer mouse, uses a peel-and-stick patch to stay on the abdomen and Bluetooth technology, which sends data directly to monitors so the care team can effectively track contractions, and maternal and fetal heart rates.
In addition, the monitor allows patients to choose how they want to labor, improving patient satisfaction and comfort, which Mount Sinai West prioritizes for all their patients.
“We continue to focus on providing technology that supports a greater patient experience, so this technology tremendously assists us in our support of patients owning their birth plans and birth experience,” Dr. Sutton says.
Specialists at the Mount Sinai West Obstetric Service support patient needs, choices, and preferences with skilled, compassionate care. Obstetricians, midwives, maternal-fetal medicine experts, and nurses partner with you to ensure you receive comprehensive services personalized to your goals.
Seated, from left: Sandra K. Masur, PhD, FASCB; Talia H. Swartz, MD, PhD, MSSM ’08, MSH ’13; Lakshmi A. Devi, PhD; Marta Filizola, PhD; Jessica R. Moise; Swan N. Thung, MD, FAASLD; and Kenneth Davis, MD, CEO of Mount Sinai Health System. Standing, from left: Patricia Kovatch; Ramon Parsons, MD, PhD; Bruce E. Sands, MD, MS; I. Michael Leitman, MD, FACS; Burton A. Cohen, MD, MSH ’79; and Dennis Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai.
The Mount Sinai Alumni Association and Icahn School of Medicine at Mount Sinai presented accomplished physicians, researchers, educators, and administrators with the 2023 Jacobi Medallion, one of Mount Sinai’s highest awards. The annual ceremony was held Wednesday, March 15 at the Plaza Hotel.
The recipients of the Jacobi Medallion have made exceptional contributions to the Mount Sinai Health System, Icahn Mount Sinai, the Mount Sinai Alumni Association, or the fields of medicine or biomedicine.
Sharon and Frederick Klingenstein/Nathan Kase, MD Professorship
Professor, Department of Pharmacological Sciences, Nash Family Department of Neuroscience, and Windreich Department of Artificial Intelligence and Human Health
As the 2023 class of medical school students from the Icahn School of Medicine at Mount Sinai filled the Guggenheim Pavilion on Friday, March 17, the air was abuzz with smiles and hugs from familiar faces. The hour drew closer to noon, and the fourth-year students, along with tens of thousands of their peers across the country, awaited the arrival of a message that would mark the next phase of their medical careers: their residency program matches on Match Day.
“This class will forever be in the history of Mount Sinai,” said Dennis Charney, MD, Anne and Joel Ehrenkranz Dean of Icahn Mount Sinai, addressing expectant attendees. The class arrived as first-year students and began their training during the thick of the COVID-19 pandemic in New York City.
“Adversity reveals character, and the way you handled the pandemic says a lot about who you are,” said Dr. Charney. “You did great. You’re going to find out in a minute or so that you matched to the best programs in the United States.”
Match Day celebrates the Main Residency Match, conducted by the National Resident Matching Program (NRMP). The program aligns the preferences of applicants with the preferences of residency programs at teaching hospitals across the nation through mathematical algorithms.
This year, Icahn Mount Sinai’s graduating MD class received their matches in a personalized bottle. They matched to many of the nation’s most competitive residency programs, spanning more than 22 specialties across the country.
Learn more about the numbers behind Match Day 2023 and celebrate these exceptional individuals with us.
Fourth-year MD students from Icahn School of Medicine at Mount Sinai received their residency matches in a personalized bottle on Match Day 2023
The 2023 Main Residency Match was the largest in NMRP’s 70-year history—with 42,952 applicants, 34,822 of whom matched to a first-year position (PGY-1)
With 81.1 percent of applicants for 2023 matched, it represents a 1 percent increase over the previous year
Mount Sinai Health System welcomes 512 new residents, who will arrive in July
The Health System’s new residents come from some of the top medical schools in the United States, including 55 Icahn Mount Sinai graduates
From Icahn Mount Sinai’s Class of 2023, comprising 137 students, 26.3 percent matched into primary care specialties, 23.4 percent matched into surgical specialties, and 40.9 percent matched into other specialties
In the other specialties, Icahn Mount Sinai’s graduating class had the most matches into psychiatry, with 8.8 percent. This was followed by anesthesiology and emergency medicine, both with 7.3 percent, and dermatology, with 5.1 percent
A record number of primary care positions were offered in the 2023 Main Residency Match. There were 571 more primary care positions than 2022, an increase of 3.2 percent over last year and an increase of 17 percent over the last five years. Primary care positions also were filled at a rate of 94.2 percent, which remained steady from last year
It has been three years since COVID-19 was declared a pandemic on March 11, 2020, by the World Health Organization. With New York City as an early epicenter, residents were hit hard. But from that experience, health care providers and researchers across the city found the opportunity to learn more about the virus and how to prepare for future pandemics.
Today, the city’s level of community transmission of COVID-19 is considered low, and the percentage of people who have completed their primary series of COVID-19 vaccinations is relatively high, according to the Centers for Disease Control and Prevention (CDC). Similarly, hospitalization and mortality rates from COVID-19 remained low in recent months, compared to the period between 2020 and 2022.
Bernard Camins, MD
These factors mean that New Yorkers can probably afford to relax their vigilance compared to previous years, notes Bernard Camins, MD, Professor of Medicine (Infectious Diseases) at the Icahn School of Medicine at Mount Sinai and Medical Director for Infection Prevention at the Mount Sinai Health System.
“We have come a long way. However, we still need to monitor how COVID-19 is affecting those who are at high risk of complications.”
Bernard Camins, MD
Who should remain vigilant?
Vulnerable groups include those who are immunocompromised, and those aged 50 and older, even if they’ve been vaccinated for COVID-19. People with certain underlying medical conditions, such as cancer; chronic kidney, lung, or liver disease; dementia; diabetes; heart conditions, or obesity are also considered at heightened risk.
For younger or healthy individuals, having COVID-19 these days might involve cold-like or mild symptoms, says Judith Aberg, MD, Chief of Infectious Diseases for the Mount Sinai Health System and Dr. George Baehr Professor of Clinical Medicine at the Icahn Mount Sinai. But vulnerable populations are at risk for developing severe disease, she adds. This includes hospitalization, needing intensive care, requiring a ventilator to breathe, or even death.
For at-risk groups, masking is recommended, as is avoiding large indoor gatherings. People planning to be organ donors should also remain vigilant for signs and symptoms of COVID-19, as an active infection could complicate one’s ability to donate, Dr. Aberg says.
“Also, people seem to have forgotten about hand hygiene; that is still important,” she notes.
What protection measures are available today?
With the federal Test to Treat initiative in place nationwide since 2022, symptomatic individuals who test positive for COVID-19 at testing sites can receive antiviral treatment, such as Paxlovid, on the spot.
“Taking Paxlovid provides that extra protection from developing complications, and the sooner it is taken, the better,” says Dr. Camins. Patients are recommended to receive antiviral treatment within five days of developing symptoms.
“One mistake people make with antivirals is that they wait to see if they feel better or worse before seeking treatment.”
Judith Aberg, MD
“If you’re a senior citizen, or have any of the underlying health conditions, when you test positive and have any symptoms, go seek treatment immediately. Do not wait,” says Dr. Aberg.
All individuals, and especially vulnerable populations, should stay up to date with COVID-19 vaccines, including the bivalent boosters, which are authorized for those ages 5 and older. “However, among people who were recommended to receive the bivalent booster, very few of them did,” Dr. Camins points out. “It seems many people have moved on regarding the pandemic before we really should.”
Judith Aberg, MD
According to the CDC, 17 percent of the U.S. population ages 5 and up have received the updated booster. In New York, that number is 18 percent.
Data have shown that the updated boosters either prevented infection or reduced the possibility of developing severe disease in people who received them. Another possible benefit of keeping up to date with vaccination is that it might prevent new variants from being as deadly as previous strains, Dr. Aberg says.
Will we need annual boosters?
Just as the bivalent boosters were updated to protect against current circulating variants and strains of SARS-CoV-2, the virus that causes COVID-19, researchers and officials are monitoring how the pathogen continues to evolve. Most of the scientific and medical community believe that the virus is headed in the direction of becoming endemic, or regularly occurring, Dr. Aberg says. “However, the jury is still out on whether annual updated boosters will be necessary,” she adds.
Neither the Food and Drug Administration nor the CDC has made any determinations on recommending annual COVID-19 shots, unlike what they have done with the flu. The data on COVID-19 collected over the recent winter could provide clarity on whether another shot might be needed this fall, says Dr. Aberg.
There are other seasonal coronaviruses and rhinoviruses that cause respiratory infections that do not require annual boosters. “It’s hard to predict whether the virus will take another turn to cause more morbidity or mortality. We’ll have to wait to see what the data shows us,” Dr. Aberg says.
What other things about COVID-19 should we be aware of?
The public health emergency declaration, which has been in place since 2020, will come to an end on Thursday, May 11, 2023. This might have implications regarding cost sharing or coverage regarding various COVID-19-related services, such as testing, treatment, or vaccinations. This might mean some services will no longer be free or will start requiring copays, depending on the insurance.
While the New York State Department of Health has not released any guidance on cost impacts, providers need to inform their patients and communities to follow up with their insurance companies and be aware of possible coverage changes, Dr. Aberg says.
“People need to be informed about potential costs before seeking COVID-19 care,” Dr. Aberg notes. “But on the other hand, we don’t want people to avoid seeking help because of cost.” If a patient experiences troubling symptoms, such as shortness of breath or fever, they should see a primary care doctor or go to the emergency room, she adds.
The medical and science community is also closer to understanding post-acute sequelae of COVID-19, or the condition colloquially known as “long COVID.”
Anyone who is infected with COVID-19 has a risk of going on to develop long COVID, in which individuals experience symptoms that persist beyond three months after the acute phase. An estimated 1 in 13 adults in the United States have long COVID, according to the CDC.
“We’re starting to zero in on specific biomarkers for people with long COVID,” says David Putrino, PhD, Director of Rehabilitation Innovation for the Mount Sinai Health System. These include platelet hyperactivation, microclots, immune dysfunction, and microbiome dysfunction.
“We are getting the science to a place where we may finally be able to identify this condition objectively.”
David Putrino, PhD
David Putrino, PhD
This has allowed providers to be better educated about the sorts of things that could cause long COVID symptoms to flare up, Dr. Putrino says. The availability of objective biomarkers also means the ability to start testing therapeutics to treat long COVID.
“A year ago, I would have thrown my hands in the air and said there were no good drug trials for long COVID,” Dr. Putrino says. “Now, I feel a little confident that we can start promising patients that these trials are on the horizon.”
“We’re getting close to getting therapeutics to prescribe. I’m hoping that will be a reality over the next two years or so,” Dr. Putrino says.
While COVID-19 community transmission, mortality, and hospitalization rates have come down across the country in recent months, the efforts to understand more about SARS-CoV-2, the virus responsible for COVID-19, continue at full speed. “The energy is still robust,” says Judith Aberg, MD, Chief of Infectious Diseases for the Mount Sinai Health System and Dr. George Baehr Professor of Clinical Medicine at the Icahn School of Medicine at Mount Sinai.
Judith Aberg, MD
Much research progress has been made since COVID-19 was declared a pandemic by the World Health Organization on March 11, 2020, but more work remains to be done.
“At all levels, from academic institutions to federal agencies, resources are still being poured into studying COVID-19 and this level of dedication is unlikely to go away anytime soon.”
Judith Aberg, MD
“It is precisely because, as a community, we have put so much effort into studying COVID-19 that we were able to learn so much about the virus and come up with vaccines and therapeutics at an unprecedented pace,” says Miriam Merad, MD, PhD, Director of the Marc and Jennifer Lipschultz Precision Immunology Institute, and Mount Sinai Professor in Cancer Immunology.
How has COVID-19 knowledge grown over the years?
A recent breakthrough was learning why COVID-19 affects older people more severely than children, says Dr. Merad. In many other respiratory diseases, such as influenza, typically both very young and very old people are most susceptible to complications.
“One of the biggest factors we’ve discovered is that age affects innate immune response,” she says. Older individuals are more likely to have a defective response in which their type I interferon activity is less likely to mount an antiviral or anti-inflammatory response, she adds.
Understanding the links of age to inflammatory response had also been a big piece in solving the COVID-19 puzzle, Dr. Merad says.
“It appears that SARS-CoV-2 might not be directly destroying organs. Rather, pathogenic-led inflammation might be doing so instead.”
Miriam Merad, MD, PhD
While SARS-CoV-2 is in the class of coronaviruses, very little was known about its specific pathophysiology, how it infects cells and induces injury, and how the host can control the virus. The scientific community has made inroads into these fields over the past year, especially in recent months, Dr. Merad notes.
Miriam Merad, MD, PhD
At the start of the pandemic, there were also no objective biomarkers to characterize the disease. Today, researchers have identified various measures, including platelet hyperactivations, microclots, and immune and microbiome dysfunction, as ways to analyze the impacts of COVID-19 on the body, especially for post-acute sequelae of COVID-19, the condition colloquially known “long COVID.”
“It’s really bleeding-edge,” says David Putrino, PhD, Director of Rehabilitation Innovation at the Mount Sinai Health System. “It has really coalesced over time, and has taken two years before impressive articles were coming out about meaningful biomarkers.”
How had COVID-19 research been challenging?
“It is really difficult to do research in the middle of a pandemic,” recalls Dr. Merad. With measures in place to keep staff safe from infection, as well as prevent lab leaks, it became challenging to develop animal models. Additionally, given that COVID-19 was a new disease, there were few good models to start with, she adds.
Barriers to knowledge, tools, or resources also made studying COVID-19 an uphill task. As the disease has symptoms that span multiple specialties, including neurology, immunology, pulmonology, cardiology, and more, an effective effort into studying the pathogen required broad capabilities.
David Putrino, PhD
“I’m a neuroscientist, focusing on electrophysiology of the brain, and had a set of tools I was comfortable using,” says Dr. Putrino. “But along came COVID-19 and suddenly I had to become an expert on immune physiology, on drawing blood, and running a wet lab.”
“Collaboration became necessary, especially with people outside our usual fields.”
David Putrino, PhD
“While I feel fortunate that I’m in a position from a funding and career standpoint that can support my needs for long COVID research, many others aren’t as fortunate to develop those skill sets,” Dr. Putrino says. The reality of many scientists needing to keep their labs running and applying for grants could mean it was easier to relegate COVID-19 research to someone else, he adds.
The nascent field of COVID-19 research, especially for long COVID, means the scientific community is still divided on various definitions. But with the pandemic dying down, researchers are able to communicate and collaborate more effectively across the country on standards and definitions when it comes to conducting research or collecting data, especially as scientific conferences return in full force, Dr. Merad says.
What are some things we still don’t know about COVID-19?
On the clinical side, it is not clear for hospitalized patients what are the best immune modulating therapies or strategies. “When should we start combination immune modulating therapies? Are antivirals effective in patients on high flow oxygen if they still are shedding virus?” says Dr. Aberg. “We are still trying to optimize modalities.”
New treatments for COVID-19, including antiviral drugs such as Paxlovid, are now available to help reduce the likeliness of developing severe disease. But some shortfalls remain.
“For example, Paxlovid has significant drug-to-drug interactions and not everyone can take that,” notes Dr. Aberg. “We’re still learning how to be able to manage those who are immunocompromised and are experiencing persistent viral shedding.”
Some of the monoclonal antibody treatments that had been developed for COVID-19 and had shown efficacy earlier in the pandemic have since become less effective against current circulating variants. “We need to develop tools for rapid sequencing of virus to detect which variant is causing disease while simultaneously having available active antibody therapies. We hope that future anti-SARS-CoV-2 monoclonal antibodies will be effective to treat and prevent COVID-19, especially for those who are immunocompromised,” Dr. Aberg says.
In basic science, many questions about viral pathophysiology remain unanswered, especially with regards to how it affects coagulation, thrombosis, and inflammation, says Dr. Merad. Even with the success of COVID-19 vaccines at reducing infection incidence and severity, people still can still be infected, and it is not clear why that is so, she adds.
What is the current state of COVID-19 research and where is it headed?
Clinicians are looking at whether they can combine different treatment modalities, especially for immunocompromised patients, says Dr. Aberg.
The National Institutes of Health is still conducting its efforts through the networks the agency has formed during the pandemic, and is conducting multicenter clinical trials, Dr. Aberg points out. It has preserved its expedited pipeline for testing novel therapeutics, including the use of “adaptive platform studies,” where new investigative agents could use an adapted template without the need for developing a new protocol from scratch.
Long COVID clinical trials are coming down the pipeline, says Dr. Putrino. A trial to test the use of Paxlovid for treating long COVID has received an Institutional Review Board approval from the Food and Drug Administration, making it one of the first of its kind for a targeted treatment of the condition, he notes.
The discovery of objective biomarkers will also pave the way for new drugs to be developed for long COVID, or for existing treatments to be explored, says Dr. Putrino.
These biomarkers could also be leveraged for uses beyond COVID-19. “The pandemic made us realize how we have few assays to measure our immune fitness to tell us whether someone can be susceptible to disease,” says Dr. Merad. Immune biomarkers could be used to develop assays to measure whether an individual could mount a good immune response, perhaps to vaccination, or just in general. “Can we build novel tools to measure our immune fitness, in the same way we can measure our blood sugar?” she questions.
It is undeniable that clinicians and researchers are committed to COVID-19 research, says Dr. Merad. “That’s what we’re fighting for,” she says. “We’re talking to everyone—industry partners, government entities—on the need for continued effort, and everyone is on board.”
Here are Some COVID-19 Research Milestones at Mount Sinai
2022
Dec 8: Mount Sinai researchers published one of the first studies about changes in blood gene expression during COVID-19 being linked to long COVID
Aug 9: Mount Sinai launched CastleVax, a clinical-stage vaccine research and development company, whose capabilities can be leveraged to tackle SARS-CoV-2
June 28: Mount Sinai-led team showed immune particles derived from the blood of a llama could provide strong protection against every COVID-19 variant
June 14: Mount Sinai researchers have developed a rapid blood assay that measures the magnitude and duration of someone’s immunity to SARS-CoV-2
Mar 31: Faculty from the Icahn School of Medicine at Mount Sinai play key roles in the SAVE program, established by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH)
Mar 21: Clinical investigators at the Icahn Mount Sinai launched a Phase 1, open-label, placebo-controlled study to evaluate the safety and immunogenicity of an egg-based COVID-19 vaccine in healthy, vaccinated adults who have never been infected with COVID-19
2021
Nov 29: Icahn Mount Sinai served as a hub site for two cohort studies as part of nationwide health consortium study by NIH on the long-term effects of SARS-CoV-2
May 25: Mount Sinai and the Pershing Square Foundation expanded a saliva-based COVID-19 testing program
April 5: Mount Sinai launched the Mount Sinai COVID-19 PCR Saliva Testing program for businesses and leisure activities in New York
Jan 27: Mount Sinai researchers demonstrated using a machine learning technique called “federated learning” to examine electronic health records to better predict how COVID-19 patients will progress
Jan 27: Scientists at University of California, San Francisco, and the Department of Microbiology at Icahn Mount Sinai reported data showing the promise and potential of Aplidin® (plitidepsin), a drug approved by the Australian Regulatory Agency for the treatment of multiple myeloma, against SARS-CoV-2
2020
Dec 29: Emergent BioSolutions and Mount Sinai initiated a clinical program to evaluate COVID-19 Human Hyperimmune Globulin product candidate in the first of two Phase 1 studies for potential post-exposure prophylaxis in individuals at high risk of exposure to SARS-CoV-2
Sept 17: The Clinical Laboratories of The Mount Sinai Hospital has received emergency use authorization from the New York State Department of Health for quantitative use of Mount Sinai’s COVID-19 antibody test
June 17: Mount Sinai submitted a request to the U.S. Food and Drug Administration (FDA) for issuance of an emergency use authorization for quantitative use of its serologic test
May 14: Mount Sinai established the Institute for Health Equity Research to understand the effects of health issues including COVID-19
April 15: Mount Sinai Laboratory, Center for Clinical Laboratories received emergency use authorization from the UFDA for an antibody test
April 3: Mount Sinai developed a new remote monitoring platform to help health care providers care for COVID-19 patients who are recovering at home
April 1: Scientists, physicians, and engineers at Mount Sinai launched STOP COVID NYC, a web-based app to capture the symptoms and spread of COVID-19 in New York City
